Trials / Terminated
TerminatedNCT01648465
Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
Phase II Multicenter Single-arm Study Evaluating the Safety and Efficacy of Everolimus as a First-line Treatment in Newly-diagnosed Patients With Advanced GI Neuroendocrine Tumors.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Hellenic Cooperative Oncology Group · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to explore the efficacy and safety of everolimus administered as a first-line treatment in newly-diagnosed patients with advanced or inoperable Gastrointestinal (GI) or pancreatic neuroendocrine tumors.
Conditions
- Gastrointestinal Tumors
- Pancreatic Tumors
- Gastrointestinal Neuroendocrine Tumors
- Pancreatic Neuroendocrine Tumors
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus | Everolimus 10mg(2x5mg)orally once daily until disease progression, unacceptable toxicity or consent withdrawal |
Timeline
- Start date
- 2012-08-06
- Primary completion
- 2017-01-01
- Completion
- 2019-08-06
- First posted
- 2012-07-24
- Last updated
- 2019-09-03
Locations
12 sites across 1 country: Greece
Source: ClinicalTrials.gov record NCT01648465. Inclusion in this directory is not an endorsement.